medigraphic.com
ISSN 2954-3835 (Digital)
ISSN 2683-2828 (Impreso)

2025, Número 4

<< Anterior Siguiente >>

Cardiovasc Metab Sci 2025; 36 (4)


El índice TG/c-HDL, marcador de dislipidemia aterogénica, es un factor significativo en el perfil epidemiológico contemporáneo de México

Nájera N, López-Dionicio Y, Meaney A, Ortiz-Vilchis P, Pérez-Ishiwara G, Juárez G, Meaney E, Ceballos G

Idioma: Inglés [English version]
Referencias bibliográficas: 75
Paginas: 197-208
Archivo PDF: 556.94 Kb.


RESUMEN

Introducción: la obesidad/sobrepeso (O/O) es la base de las principales causas de mortalidad general en México: cardiopatía isquémica y diabetes mellitus tipo 2 (DM2). La tríada lipídica, asociada con O/O, es el tipo más común de dislipidemia en nuestro país. Analizamos los perfiles lipídicos de una muestra amplia de la población urbana contemporánea de la Ciudad de México. Material y métodos: sesenta y ocho mil participantes conformaron esta cohorte. No se registró el estado clínico, el motivo del estudio ni si el paciente estaba recibiendo tratamiento. Se midieron espectrofotométricamente los niveles de colesterol total (CT), triglicéridos (TG) y colesterol unido a lipoproteínas de alta densidad (c-HDL). Se calcularon los niveles de lipoproteínas de baja densidad (c-LDL) y no HDL, y las razones de riesgo CT/c-HDL, c-LDL/c-HDL y TG/c-HDL. Los criterios de clasificación se basaron en el ATP III y las guías europeas. Se estimaron los valores medios y las distribuciones de cuartiles de todos los lípidos y lipoproteínas y se estratificaron por sexo. Resultados: los valores de CT estuvieron por encima del punto de corte. Los valores de TG fueron significativamente mayores que este. Los niveles de c-HDL en ambos sexos se mantuvieron cerca del límite inferior. Los niveles de c-LDL estuvieron entre 100 y 130 mg/dL tanto en hombres como en mujeres. Los niveles de c-no-HDL nunca alcanzaron un punto de corte de 160 mg/dL. El índice c-LDL/c-HDL estuvo por debajo de este. Curiosamente, los valores de TG/c-HDL estuvieron por encima del límite de corte. Conclusiones: la hipertrigliceridemia, causada por la obesidad abdominal, es la anormalidad lipídica más crítica en la población mexicana. TG/c-HDL es un marcador de riesgo fácilmente disponible y de bajo costo que debe usarse de forma rutinaria.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Beltrán-Sánchez H, Drumond-Andrade FC, Riosmena F. Contribution of socioeconomic factors and health care access to the awareness and treatment of diabetes and hypertension among older Mexican adults. Salud Publica Mex. 2015; 57 suppl. 1: s06-s14. Available in: https://saludpublica.mx/index.php/spm/article/view/7584

  2. Stevens G, Dias RH, Thomas KJA, Rivera JA, Carvalho N, Barquera S et al. Characterizing the epidemiological transition in Mexico: National and subnational burden of diseases, injuries, and risk factors. PLoS Med. 2008; 5: e163. doi: 10.1371/journal.pmed.0050163.

  3. Barquera S, Rivera JA. Obesity in Mexico: rapid epidemiological transition and food industry interference in health policies. Lancet Diabetes Endocrinol. 2020; 8: 746-747. doi: 10.1016/S2213-8587(20)30269-24.

  4. INEGI. Estadísticas de Defunciones Registradas (EDR) 2023 (preliminar). Comunicado de prensa núm. 478/24; 8 de agosto de 2024 [Internet]. México: Instituto Nacional de Estadística y Geografía; 2024. Available in: https://www.inegi.org.mx/contenidos/saladeprensa/boletines/2024/EDR/EDR2023_ene-dic.pdf

  5. Rtveladze K, Marsh T, Barquera S, Sánchez Romero LM, Levy D, Meléndez G et al. Obesity prevalence in Mexico: impact on health and economic burden. Public Health Nutr. 2014; 17: 233-239. doi: 10.1017/S1368980013000086.

  6. Martín JA, Mosqueira A, Fernández Labardini MT, Mainero Ruíz C, Vizzani R et al. Bill of amendment to the pensions system in Mexico [Internet]. White & Case; 2020. Available in: https://www.whitecase.com/insight-alert/bill-amendment-pensions-system-mexico

  7. Popkin BM. Is the obesity epidemic a national security issue around the globe? Curr Opin Endocrinol Diabetes Obes. 2011; 18: 328-331. doi: 10.1097/MED.0b013e3283471c74.

  8. Zimmet P. Globalization, coca-colonization and the chronic disease epidemic: can the doomsday scenario be averted? J Intern Med. 2201; 47: 301-310. doi: 10.1046/j.1365-2796.2000.00625.x.

  9. Alpízar-Salazar A, Alpízar-Sánchez MR, De Aldecoa-Castillo JM, Romero-Cervantes A, Alpízar MF, Frydman TD. Chronic degenerative diseases before and after the COVID-19 pandemic in Mexico. Biomed J Sci Tech Res. 2020; 28 (2): 2020. doi: 10.26717/BJSTR.2020.28.004627.

  10. Torres F, Rojas A. Obesity and public health in Mexico: transforming the hegemonic food supply and demand pattern. Problemas del Desarrollo. Revista Latinoamericana de Economía. 2018; 49 (193): 145-169.

  11. Arroyave-Loaiza MG, Jarillo-Soto EC, López-Arellano O, Arellano-Navarro CE, Delgado-Campos VI. Proposal to estimate the required resources for healthcare. Salud Publica Mex. 2024; 66: 732-740. Available in: https://saludpublica.mx/index.php/spm/article/view/15381

  12. Villalpando S, Shamah-Levy T, Rojas R, Aguilar-Salinas CA. Trends for type 2 diabetes and other cardiovascular risk factors in Mexico from 1993–2006. Salud Publica Mex. 2010; 52: S72-S79. doi: 10.1590/S0036-36342010000700011.

  13. Rivas-Gomez B, Almeda-Valdés P, Tussié-Luna MT, Aguilar-Salinas CA. Dyslipidemia in Mexico, a call for action. Rev Invest Clin. 2018; 70: 211-216. doi: 10.24875/RIC.18002573.

  14. Meaney A, Ceballos-Reyes G, Gutiérrez-Salmean G, Samaniego-Méndez V, Vela-Huerta A, Alcocer L et al. Cardiovascular risk factors in a Mexican middle-class urban population. The Lindavista Study. Baseline data. Arch Cardiol Mex. 2013; 83 (4): 249-256. doi: 10.1016/j.acmx.2013.05.002.

  15. Manoria PC, Chopra HK, Parashar SK, Dutta AL, Pinto B, Mullasari A et al. The nuances of atherogenic dyslipidemia in diabetes: focus on triglycerides and current management strategies. Indian Heart J. 2013; 65 (6): 683-690. doi: 10.1016/j.ihj.2013.10.015.

  16. Estrada García T, Meaney A, López-Hernández D, Meaney E, Sánchez-Hernández O, Rodríguez Arellano E et al. Hypertension and lipid triad are the most important attributable risks for myocardial infarction in a middle class urban Mexican population. Ann Nutr Metabol. 2013; 63: 1343.

  17. Pavía-López AA, Alcocer-Gamba MA, Ruiz-Gastelum ED, Mayorga-Butrón JL, Mehta R, Díaz-Aragón FA et al. Guía de práctica clínica mexicana para el diagnóstico y tratamiento de las dislipidemias y enfermedad cardiovascular aterosclerótica. Arch Cardiol Méx. 2022; 92 suppl: 1-62. doi: 10.24875/ACM.M22000081.

  18. Gaziano JM, Hennekens CH, O'Donnell CJ, Breslow JL, Buring JE. Fasting triglycerides, high-density lipoprotein, and risk of myocardial infarction. Circulation. 1997; 96: 2520-2525. doi: 10.1161/01.CIR.96.8.2520.

  19. Kosmas CE, Rodriguez Polanco S, Bousvarou MD, Papakonstantinou EJ, Peña Genao E, Guzman E et al. The Triglyceride/High-Density Lipoprotein Cholesterol (TG/HDL-C) Ratio as a risk marker for metabolic syndrome and cardiovascular disease. Diagnostics (Basel). 2023; 13: 929. doi: 10.3390/diagnostics13050929.

  20. Chauhan A, Singhal A, Goyal P. TG/HDL Ratio: A marker for insulin resistance and atherosclerosis in prediabetics or not? J Family Med Prim Care. 2021; 10 (10): 3700-3705. doi: 10.4103/jfmpc.jfmpc_165_21.

  21. Martínez-Marroquín Y, Meaney A, Samaniego-Méndez V, Nájera N, Ceballos G, Fernández-Barros C et al. The TG/HDL-c lipid ratio as a cardiovascular risk marker in a Mexican urban middle-class population: Do we need a risk score tailored for Mexicans? J Clin Med. 2023; 12 (18): 6005. doi: 10.3390/jcm12186005.

  22. Dixon JR Jr. The International Conference on Harmonization Good Clinical Practice guideline. Qual Assur. 1998; 6 (2): 65-74. doi: 10.1080/105294199277860.

  23. World Medical Association. World Medical Association Declaration of Helsinki: ethical principles for medical research involving human subjects. JAMA. 2013; 310 (20): 2191-2194. doi: 10.1001/jama.2013.281053.

  24. Diario de la Federación. Ley General de Salud [Internet]. México: Diario Oficial de la Federación; [accessed on February 4th 2025]. Available in: http://www.cnts.salud.gob.mx/descargas/LEY_GENERAL_DE_SALUD.pdf

  25. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972; 18: 499-502.

  26. Blaha MJ, Blumenthal RS, Brinton EA, Jacobson TA. The importance of non–HDL cholesterol reporting in lipid management. J Clin Lipidol. 2008; 2: 267-273. doi: 10.1016/j.jacl.2008.06.013.

  27. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001; 285: 2486-2497. doi: 10.1001/jama.285.19.2486.

  28. Visseren FLJ, Mach F, Smulders YM, Carballo D, Koskinas KC, Back M et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice. Eur Heart J. 2021; 42 (34): 3227-3337. doi: 10.1093/eurheartj/ehab484.

  29. Grundy SM. Metabolic syndrome: a multiplex cardiovascular risk factor. J Clin Endocrinol Metab. 2007; 92: 399-404. doi: 10.1210/jc.2006-0513.

  30. Castelli WP, Abbott RD, McNamara PM. Summary estimates of cholesterol used to predict coronary heart disease. Circulation. 1983; 67: 730-734. doi: 10.1161/01.cir.67.4.730.

  31. Zhou D, Liu X, Lo K, Huang Y, Feng Y. The effect of total cholesterol/high-density lipoprotein cholesterol ratio on mortality risk in the general population. Front Endocrinol (Lausanne). 2022; 13: 1012383. doi: 10.3389/fendo.2022.1012383.

  32. Chen QJ, Lai HM, Chen BD, Li XM, Zhai H, He C et al. Appropriate LDL-C-to-HDL-C ratio cut-offs for categorization of cardiovascular disease risk factors among Uygur adults in Xinjiang, China. Int J Environ Res Public Health. 2016; 13: 235. doi: 10.3390/ijerph13020235.

  33. Sun T, Chen M, Shen H, Yin O, Fan L, Chen X. Predictive value of LDL/HDL ratio in coronary atherosclerotic heart disease. BMC Cardiovasc Disord. 2022; 22: 273. doi: 10.1186/s12872-022-02706-6.

  34. Hu S, Fan H, Zhang S, Chen C, You Y, Wang C et al. Association of LDL-C/HDL-C ratio with coronary heart disease: A meta-analysis. Indian Heart J. 2024; 76 (2): 79-85. doi: 10.1016/j.ihj.2024.01.014.

  35. Ferreira da Silva E, Cotta RMM, Mendonça ET, de Oliveira DM, Cardoso SA, Colodette RA et al. Optimal cut-off of the TG/HDL-c ratio for cardiovascular risk in hypertensive and diabetic patients monitored by primary health care in a city in Minas Gerais. Int J Cardiovasc Sci. 2021; 34 (5 Suppl 1): 55-65. doi: 10.36660/ijcs.20200290.

  36. Meaney A, Martínez-Marroquín MY, Samaniego-Méndez V, Fernández-Barros C, Hidalgo I, Nájera N et al. In search of an appropriate risk scale for Mexicans. The insufficiencies of the Globorisk scale. Cardiovasc Metab Sci. 2024;35: 6-15. https://dx.doi.org/10.35366/114999.

  37. 37 Goff DC Jr, Lloyd-Jones DM, Bennett G, Coady S, D'Agostino RB, Gibbons R et al. 2013 ACC/AHA Guideline on the Assessment of Cardiovascular Risk: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014; 129 (Suppl. S2): S49-S73. doi: 10.1161/01.cir.0000437741.48606.98.

  38. Medina C, Tolentino-Mayo L, López-Ridaura R, Barquera S. Evidence of increasing sedentarism in Mexico City during the last decade: Sitting time prevalence, trends, and associations with obesity and diabetes. PLoS One. 2017; 12: e0188518. doi: 10.1371/journal.pone.0188518.

  39. Tsegyie WondmkunY. Obesity, insulin resistance, and type 2 diabetes: Associations and therapeutic implications. Diabetes Metab Syndr Obes. 2020; 13: 3611-3616. doi: 10.2147/DMSO.S275898.

  40. Lee SH, Park SY, Choi S. Insulin resistance: from mechanisms to therapeutic strategies. Diabetes Metab J. 2022; 46 (1): 15-37. doi: 10.4093/dmj.2021.0280.

  41. Eckel RH, Kahn SE, Ferrannini E, Goldfine AB, Nathan DM, SchwartznMW. Obesity and type 2 diabetes: what can be unified and what needs to be individualized? J Clin Endocrinol Metab. 2011; 96: 1654-1663. doi: 10.1210/jc.2011-0585.

  42. Roberts CK, Hevener AL, Barnard RJ. Metabolic syndrome and insulin resistance: underlying causes and modification by exercise training. Compr Physiol. 2013; 3 (1): 1-58. doi: 10.1002/cphy.c110062.

  43. Chopra AK. Metabolic syndrome or insulin resistance: Evolution, controversies and association with cardiovascular disease risk. Indian J Clin Cardiol. 2020; 1: 77-85. doi: 10.1177/2632463620935030.

  44. Mottillo S, Filion K, Genest J, Joseph L, Pilote L, Poirier P et al. The metabolic syndrome and cardiovascular risk. J Am Coll Cardiol. 2010; 56: 1113-1132. doi: 10.1016/j.jacc.2010.05.034.

  45. Tune JD, Goodwill AG, Sasoon DJ, Mather KJ. Cardiovascular consequences of metabolic syndrome. Transl Res. 2017; 183: 57-70. doi: 10.1016/j.trsl.2017.01.001.

  46. Grundy SM. Atherogenic dyslipidemia associated with metabolic syndrome and insulin resistance. Clin Cornerstone. 2006; 8 Suppl 1: S21-S27. doi: 10.1016/s1098-3597(06)80005-0.

  47. Lorenzatti AJ, Toth PP. New perspectives on atherogenic dyslipidaemia and cardiovascular disease. Eur Cardiol. 2020; 15: 1-9. doi: 10.15420/ecr.2019.06.

  48. Rizzo M, Berneis K. Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention? J Atheroscler Thromb. 2005; 12: 23723-23729. doi: 10.5551/jat.12.237.

  49. Rizvi AA, Stoian AP, Janez A, Rizzo M. Lipoproteins and cardiovascular disease: an update on the clinical significance of atherogenic small, dense LDL and new therapeutical options. Biomedicines. 2021; 9 (11): 1579. doi: 10.3390/biomedicines9111579.

  50. Ikezaki H, Lim E, Cupples LA, Liu CT, Asztalos BF, Schaefer EJ. Small dense low?density lipoprotein cholesterol is the most atherogenic lipoprotein parameter in the Prospective Framingham Offspring Study. Am Heart J. 2021; 10: e019140. doi: 10.1161/JAHA.120.019140.

  51. Essilfie G, Shavelle DM, Tun H, Platt K, Kobayashi R, Mehra A et al. Association of elevated triglycerides and acute myocardial infarction in young Hispanics. Cardiovasc Revasc Med. 2016; 17 (8): 510-514. doi: 10.1016/j.carrev.2016.06.001.

  52. Arca M, Veronesi C, D'Erasmo L, Borghi C, Colivicchi F, De Ferrari GM et al. Association of hypertriglyceridemia with all-cause mortality and atherosclerotic cardiovascular events in a low-risk Italian population: The TG-REAL retrospective cohort analysis. J Am Heart Assoc. 2020; 9 (19): e015801. doi: 10.1161/JAHA.119.015801.

  53. Chen Z, Chen G, Qin H, Cai Z, Huang J, Chen H et al. Higher triglyceride to high-density lipoprotein cholesterol ratio increases cardiovascular risk: 10-year prospective study in a cohort of Chinese adults. J Diabetes Investig. 2019; 11: 475-481. doi: 10.1111/jdi.13118.

  54. Assmann G, Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Münster study. Am J Cardiol. 1992; 70 (7): 733-737. doi: 10.1016/0002-9149(92)90550-i.

  55. Saadatagah S, Pasha AK, Alhalabi L, Sandhyavenu H, Farwati M, Smith CY et al. Coronary heart disease risk associated with primary isolated hypertriglyceridemia; a population-based study. J Am Heart Assoc. 2021; 10 (11): e019343. doi: 10.1161/JAHA.120.019343.

  56. Farnier M, Zeller M, Masson D, Cottin Y. Triglycerides and risk of atherosclerotic cardiovascular disease: An update. Arch Cardiovasc Dis. 2021; 114: 132-139. doi: 10.1016/j.acvd.2020.11.006.

  57. Sarwar N, Danesh J, Eiriksdottir G, Sigurdsson G, Wareham N, Bingham S et al. Triglycerides and the risk of coronary heart disease. 10,158 incident cases among 262,525 participants in 29 Western prospective studies. Circulation. 2007; 115: 450-458. doi: 10.1161/CIRCULATIONAHA.106.637793.

  58. Ye X, Kong W, Zafar MI, Chen LL. Serum triglycerides as a risk factor for cardiovascular diseases in type 2 diabetes mellitus: a systematic review and meta-analysis of prospective studies. Cardiovasc Diabetol. 2019; 18: 48. doi: 10.1186/s12933-019-0851-z.

  59. Vallejo-Vaza AJ, Corral P, Schreier L, Raya KK. Triglycerides and residual risk. Curr Opin Endocrinol Diabetes Obes. 2020; 27: 95-103. doi: 10.1097/MED.0000000000000530.

  60. Hajifathalian K, Ueda P, Lu Y, Woodward M, Ahmadvand A, Aguilar-Salinas CA et al. A novel risk score to predict cardiovascular disease risk in national populations (Globorisk): A pooled analysis of prospective cohorts and health examination surveys. Lancet Diabetes Endocrinol. 2015; 3: 339-355. doi: 10.1016/S2213-8587(15)00081-9.

  61. Khan SS, Coresh J, Pencina MJ, Ndumele CE, Rangaswami J, Chow DL et al. Novel prediction equations for absolute risk assessment of total cardiovascular disease incorporating cardiovascular-kidney-metabolic health: A Scientific Statement from the American Heart Association. Circulation. 2023; 148: c1982-2004. doi: 10.1161/CIR.0000000000001191.

  62. Vekic J, Zeljkovic A, Cicero AFG, Janez A, Pantea Stoian A, Sonmez A et al. Atherosclerosis development and progression: The role of atherogenic small, dense LDL. Medicina (Kaunas). 2022; 58: 299. doi: 10.3390/medicina58020299.

  63. Galeano NF, Al-Haideri M, Keyserman F, Rumsey SC, Deckelbaum RJ. Small dense low density lipoprotein has increased affinity for LDL receptor-independent cell surface binding sites: a potential mechanism for increased atherogenicity. J Lipid Res. 1998; 39 (6): 1263-1273.

  64. Millán J, Pintó X, Muñoz A, Zúñiga M, Rubiés-Prat J, Pallardo LF et al. Lipoprotein ratios: Physiological significance and clinical usefulness in cardiovascular prevention. Vasc Health Risk Manag. 2009; 5: 757-765.

  65. Caselli C, De Caterina R, Smit JM, Campolo J, El Mahdiui M, Ragusa R et al. Triglycerides and low HDL cholesterol predict coronary heart disease risk in patients with stable angina. Sci Rep. 2021; 11 (1): 20714. doi: 10.1038/s41598-021-00020-3.

  66. Baez-Duarte BG, Zamora-Gínez I, González-Duarte R, Torres-Rasgado E, Ruiz-Vivanco G, Pérez-Fuentes R et al. Triglyceride/high-density lipoprotein cholesterol (TG/HDL-C) index as a reference criterion of risk for metabolic syndrome (MetS) and low insulin sensitivity in apparently healthy subjects. Gac Med Mex. 2017; 153 (2): 152-158.

  67. Rodríguez-Gutiérrez N, Vanoye Tamez M, Vázquez-Garza E, Villarreal-Calderón JR, Castillo EC, Laresgoiti-Servitje E et al. Association of the triglyceride/high-density lipoprotein cholesterol index with insulin resistance in a pediatric population in northeast Mexico. Metab Syndr Relat Disord. 2020; 18 (7): 333-340. doi: 10.1089/met.2020.0046.

  68. Murguía-Romero M, Jiménez-Flores JR, Sigrist-Flores SC, Tapia-Pancardo DC, Jiménez-Ramos A, Méndez-Cruz AR et al. Prevalence of metabolic syndrome in young Mexicans: a sensitivity analysis on its components. Nutr Hosp. 2015; 32 (1): 189-195. doi: 10.3305/nh.2015.32.1.9031.

  69. González-Chávez A, Simental-Mendía LE, Elizondo-Argueta S. Elevated triglycerides/HDL-cholesterol ratio associated with insulin resistance. Cir Cir. 2011; 79 (2): 126-131.

  70. Borrayo G, Basurto L, González-Escudero E, Diaz A, Vázquez A, Sánchez L. TG/HDL-c ratio as cardio-metabolic biomarker even in normal weight women. Acta Endocrinol. 2018; 14: 261-267. doi: 10.4183/aeb.2018.261.

  71. Hernández-Alcaraz C, Aguilar-Salinas CA, Mendoza-Herrera K, Pedroza-Tobías A, Villalpando S, Shamah-Levy T et al. Prevalencia de dislipidemias, diagnóstico previo, tratamiento y control: resultados de la Ensanut 2012. Salud Publica Mex. 2020; 62 (2): 137-146. doi:10.21149/10520.

  72. Fanghanel-Salmón G, Gutiérrez-Salmeán G, Samaniego V, Meaney A, Sánchez-Reyes L, Navarrete U et al. Obesity phenotypes in urban middle-class cohorts; the prit-Lindavista merging evidence in Mexico: the opus prime study. Nutr Hosp. 2015; 32 (1): 182-188. doi: 10.3305/nh.2015.32.1.8646..

  73. Aguilar-Salinas CA, Olaiz G, Valles V, Torres JM, Gómez Pérez FJ, Rull JA et al. High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nationwide survey. J Lipid Res. 2001; 42 (8): 1298-1307.

  74. Aguilar-Salinas CA, Gómez-Pérez FJ, Rull J, Villalpando S, Barquera S, Rojas R. Prevalence of dyslipidemias in the Mexican National Health and Nutrition Survey 2006. Salud Publica Mex. 2010; 52 Suppl 1: S44-s53. doi: 10.1590/s0036-36342010000700008.

  75. Shamah-Levy T, Romero-Martínez M, Barrientos-Gutiérrez T, Cuevas-Nasu L, Bautista-Arredondo S, Colchero MA et al. Encuesta Nacional de Salud y Nutrición 2020 sobre Covid-19. Resultados nacionales. Cuernavaca, México: Instituto Nacional de Salud Pública; 2021.




2020     |     www.medigraphic.com